| |
Contact SRI Biosciences
Chemical, Biological, Radiological, and Nuclear Countermeasures
SRI Biosciences is a major contributor to the development of medical countermeasures for chemical, biological, radiological, and nuclear (CBRN) threats that may be used against military or civilian populations.
Examples of our efforts related to homeland security and national defense include:
• CounterAct program through the National Institute of Neurological Disorders and Stroke (NINDS), for preclinical development of therapeutics against chemical warfare agents
• Division of Microbiology and Infectious Disease (DMID) of the National Institute of Allergy and Infectious Disease (NIAID), for the development of therapeutics and vaccines against a wide variety of biodefense pathogens
• Biomedical Advanced Research and Development Authority (BARDA) contract for the development of animal models for evaluation of medical countermeasures for biological and radiological/nuclear agents
• NIAID contracts and grants for the development of an oral drug for chelation of radioisotopes
• Defense Threat Reduction Agency (DTRA) contract, "Accelerated Path to Safe and Effective Therapeutics (APSET) for Bioterrorism Agents", for repurposing of Food and Drug Administration (FDA)-approved drugs against selected biothreats to identify therapeutics with appropriate safety profiles and broad spectrum activity
Relevant federal contracts and grants to SRI, ongoing and recent, that are related to CBRN countermeasures:
SRI's CBRN-RELATED CONTRACTS and GRANTS with the U.S. GOVERNMENT |
| Agency |
Descriptive Title |
| BARDA |
Animal Model Development for Chemical, Biological, Radiological & Nuclear Medical Countermeasures |
| BARDA |
Contract Research Organization (CRO) Services for Safety and Toxicology Studies |
| DHS |
Immunological Assays (ELISA) for the Detection Of Ricin, Abrin, and Botulinum Toxins |
| DHS |
Viral Genetic Stability in a Forensics Context (VGSFC) |
| DTRA |
An Accelerated Path to Safe and Effective Therapeutics (APSET) for Bioterrorism Agents |
| DTRA |
Broad-Spectrum Agents for Prophylaxis and Treatment Against Bacterial Threats |
| NIAID |
In Vitro and Animal Models for Emerging Diseases and Biodefense |
| NIAID |
NIAID Biodefense Program |
| NIAID |
Development of Improved Diethylenetriaminepentaacetate (DTPA) for Radionuclide Chelation |
| NIAID |
Development of an Oral Form of Diethylenetriaminepentaacetate (DTPA) for Use in Radionuclide Decorporation—Radiological Emergency |
| NIAID |
Production of Monoclonal Antibody Based Therapeutics for Botulism |
| NIAID |
Neutralizing Botulinum Neurotoxin with Human Antibodies |
| NIAID |
Preclinical Development of Therapeutic Agents for the Division of Microbiology and Infectious Diseases (DMID) |
| NIAID |
Product Development Plans for Vaccines |
| NIAID |
Safety Evaluation of Anti-Infective Agents |
| NIAID |
In Vitro Screening for Antimicrobial Activity |
| NINDS |
Countermeasures Against Chemical Threats (CounterACT) Preclinical Development Facilities |
| USAMRAA |
Epic 06—Engineered Pathogen Identification and Countermeasures Program—Bug-To-Drug |
| USAMRAA |
Advancing Novel Dietary Indole Analogs into Preclinical Studies |
| USAMRAA |
Analytical, Characterization, and Stability Studies of Organic Chemicals, Bulk Drugs, and Drug Formulation |
BARDA: Biomedical Advanced Research and Development Authority
DHS: Department of Homeland Security
DMID: Division of Microbiology and Infectious Diseases
DTRA: Defense Threat Reduction Agency
NIAID: National Institute of Allergy and Infectious Diseases
NINDS: National Institute of Neurological Disorders and Stroke
USAMRAA: United States Army Medical Research Acquisition Activity |
Related Capabilities
SRI can perform a complete portfolio of research and development activities including drug and biomarker discovery, custom synthesis, animal model development, in vitro and in vivo efficacy, pharmacokinetics and metabolism, safety testing, clinical manufacturing, regulatory support, and a variety of other services. We perform this work for the U.S. government, academic institutions, foundations and biotechnology and pharmaceutical companies, and can also provide resources to outside organizations for teaming on large government opportunities. Click here for a full list of our research and development capabilities.
Selected Articles
Drug Development Research, June 2009, Volume 70, Issue 4
Special Issue: Biodefense Countermeasure Development
Edited by Lynne Gilfillan, SRI International
Articles by SRI staff
Gilfillan, L.
Development of Medical Countermeasures for Biodefense: How Far Have We Come in Seven Years?
Manger, I, Pearson, J, Winegar, R. Gilfillan L.
Tools for Planning and Coordinating Development of Medical Countermeasures in the Public Sector.
Stahl AM, Adler, M. Millard, CB, and Gilfillan L.
Accelerating Botulism Therapeutic Product Development in the Department of Defense.
Vaidyanathan R, Kodukula K.
Using a Systems Biology Approach to Dissect Parasite–Host Interactions
Addtional Biosciences publications
You Make the Call
For further information, contact our Client Services Team:
Toll-Free: (866) 451-5998
Phone: (650) 859-3000
Fax: (650) 859-3041
Email: biosciences@sri.com
Contact SRI Biosciences
Last Updated Jul 5, 2011
|
|
R&D Divisions